Skip to content


Open Access

Prostaglandin D2 enhances interleukin -1beta-induced cyclooxygenase-2 expression in osteoarthritic cartilage

  • N Zayed1,
  • F E El Mansouri1,
  • N Chabane1,
  • J Martel-Pelletier1,
  • J P Pelletier1 and
  • H Fahmi1
Journal of Translational Medicine20108(Suppl 1):P61

Published: 25 November 2010


Signalling PathwaymRNA ExpressionProstaglandinIndomethacinSelective Agonist


To investigate the effects of prostaglandin D2 (PGD2) on interleukin-1beta (IL-1beta)-induced cyclooxygenase (COX)-2 expression in human cartilage and the signalling pathways involved in these effects.


Chondrocytes were stimulated with IL-1 in the presence or absence of PGD2, and expression of COX-2 protein was evaluated by western-blotting. Messenger RNA (mRNA) expression was analyzed by real-time reverse transcription-polymerase chain reaction. The role of the PGD2 receptors D prostanoid receptor 1 (DP1) and chemoattractant receptor-like molecule expressed on Th2 cells (CRTH2) was evaluated using specific agonists.


PGD2 increased in a dose-dependent manner IL-1-induced COX-2 protein and mRNA expression. DP1 and CRTH2 were expressed and functional in chondrocytes. The effect of PGD2 was mimicked by DK-PGD2 and Indomethacin, selective agonists of CRTH2, but not by BW245C, a selective agonist of DP1. Furthermore, treatment with an anti-CRTH2 antibody reversed the effect of PGD2, indicating that the stimulatory effect of PGD2 is mediated by CRTH2. Activation of CRTH2 is consistent with the activation of a receptor coupled to a phosphoinositide-specific phospholipase, suggesting that the effect of PGD2 is mediated by the CRTH2/PIP2/PKC.


PGD2 stimulates IL-1-induced production of COX-2 by chondrocytes through the CRTH2/PIP2/PKC signalling pathway.

Authors’ Affiliations

Osteoarthritis Research Unit, Research Centre of the University of Montreal Hospital Center (CR-CHUM), Notre-Dame Hospital, Montreal, Canada


© Zayed et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.